heparin

(redirected from Low molecular weight heparin)
Also found in: Thesaurus, Medical, Acronyms, Encyclopedia, Wikipedia.
Related to Low molecular weight heparin: Enoxaparin

hep·a·rin

 (hĕp′ər-ĭn)
n.
1. An acidic glycosaminoglycan found especially in lung and liver tissue and having the ability to slow the clotting of blood, used as a drug in the treatment of thrombosis. Also called unfractionated heparin.
2. Any of several anticoagulants, such as enoxaparin, that are derived from this compound by depolymerization and have a lower molecular weight and somewhat different pharmacological properties. Also called low-molecular-weight heparin.

[Late Latin hēpar, liver (from Greek; see yē̆kw in Indo-European roots) + -in.]
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.

heparin

(ˈhɛpərɪn)
n
(Biochemistry) a polysaccharide, containing sulphate groups, present in most body tissues: an anticoagulant used in the treatment of thrombosis
[C20: from Greek hēpar the liver + -in]
ˈheparinˌoid adj
Collins English Dictionary – Complete and Unabridged, 12th Edition 2014 © HarperCollins Publishers 1991, 1994, 1998, 2000, 2003, 2006, 2007, 2009, 2011, 2014

hep•a•rin

(ˈhɛp ə rɪn)

n.
a polysaccharide present in animal tissues, esp. the liver, that has anticoagulant properties and is used to prevent or dissolve blood clots.
[1915–20; < Greek hêpar liver + -in1]
Random House Kernerman Webster's College Dictionary, © 2010 K Dictionaries Ltd. Copyright 2005, 1997, 1991 by Random House, Inc. All rights reserved.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.heparin - a polysaccharide produced in basophils (especially in the lung and liver) and that inhibits the activity of thrombin in coagulation of the blood; it (trade names Lipo-Hepin and Liquaemin) is used as an anticoagulant in the treatment of thrombosis and in heart surgery
anticoagulant medication, decoagulant - medicine that prevents or retards the clotting of blood
polyose, polysaccharide - any of a class of carbohydrates whose molecules contain chains of monosaccharide molecules
Based on WordNet 3.0, Farlex clipart collection. © 2003-2012 Princeton University, Farlex Inc.
Translations

hep·a·rin

n. heparina, sustancia que actúa como anticoagulante.
English-Spanish Medical Dictionary © Farlex 2012

heparin

n heparina; low-molecular-weight — heparina de bajo peso molecular
English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
References in periodicals archive ?
The global low molecular weight heparin market size was valued at US$ 2,882.6 Mn in 2017 and is expected to witness a CAGR of 6.7% during the forecast period (2018 - 2026).
(5.) Qiu F, Lu XS, Huang YK Effect of low molecular weight heparin on pancreatic micro-circulation in severe acute pancreatitis in a rodent model.
Unfractionated heparin versus low molecular weight heparin for avoiding heparin-induced thrombocytopenia in postoperative patients.
Lazo-Langner, "The effect of low molecular weight heparin on survival in cancer patients: An updated systematic review and meta-analysis of randomized trials," Journal of Thrombosis and Haemostasis, vol.
Gent et al., "An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial," Thrombosis Research, vol.
Low Molecular Weight Heparin (LMWH): Low Molecular Weight Heparins are coagulation inhibiting glycosaminoglycans.
Extended outpatient therapy with low molecular weight heparin for the treatment of recurrent venous thromboembolism despite warfarin therapy.
Compared with control group, the content of total protein in BALF in both saline nebulization group and low molecular weight heparin nebulization group increased significantly (P < 0.05, Figure 2), while content of total protein in BALF in LMWH nebulization group decreased significantly compared to saline nebulization group (P < 0.05, Figure 2).
Third, platelet counts increased gradually within 48 h of discontinuation of UFH and Low molecular weight heparin and returned to 88 x 10 [sup]9 /L within 5 days.
The effect of low molecular weight heparin on survival in patients with advanced malignancy.
The vitreous infusion consisted of 250 g/ml of 5-fluorouracil (FFU) and 1 lU/ml of low molecular weight heparin (LMWH).

Full browser ?